| "The non-surgical treatment of thyroid cancer is outlined." | ( Halnan, KE, 1975) |
| "Ten athyreotic patients, treated for thyroid carcinoma, were randomly assigned to receive L-T4 sodium 0." | ( Ladenson, PW; Sherman, SI, 1992) |
| "Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5." | ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991) |
| "All had differentiated thyroid cancer, treated by partial or total thyroidectomy and/or 131I ablation, and were receiving suppressive thyroxine therapy." | ( Black, EG; Sheppard, MC, 1991) |
| "Twenty-nine patients with advanced thyroid cancer have been treated with sequential chemotherapy regimes using the single agents etoposide, carboplatin, cis-platinum or methotrexate, and the combination of adriamycin, bleomycin and vincristine (ABC)." | ( Harmer, C; Hoskin, PJ, 1987) |
| "The incidence of thyroid adenomas and carcinomas were 69% (9/13) and 15% (2/13), respectively, in rats treated with DHPN alone, 0% (0/15) and 6% (1/15) in rats treated with DHPN and 0." | ( Fukumoto, M; Hiasa, Y; Kitahori, Y; Nakaoka, S; Ohshima, M, 1989) |
| "The incidence of thyroid adenomas at the end of week 20 of the experiment was 100% (20/20) in rats treated with DHPN followed by KClO4, 85% (17/20) in rats given DHPN followed by KI, 95% (19/20) in rats given DHPN followed by PTU, and 5% (1/20) in rats given DHPN alone." | ( Hashimoto, H; Hiasa, Y; Kato, Y; Kitahori, Y; Konishi, N; Minami, S; Murata, Y; Ohshima, M; Sakaguchi, Y; Shimoyama, T, 1987) |
| "Deaths from thyroid cancer may occur many years after diagnosis, and such an indolent course has hampered the analysis of the multiple treatment programs advocated." | ( Freitas, JE; Gross, MD; Ripley, S; Shapiro, B, 1985) |
| "The incidence of thyroid adenomas and cancers was 20% (4/20) and 10% (2/20) in rats treated with DHPN alone." | ( Hashimoto, H; Hiasa, Y; Katoh, Y; Kitahori, Y; Konishi, N; Minami, S; Murata, Y; Ohshima, M; Sakaguchi, Y; Shimoyama, T, 1987) |
| "Twenty-four patients with metastatic thyroid cancer were treated with aclarubicin intravenously at a dose of 25-30 mg/m2 daily for 4 days and treatment was repeated every 3 weeks." | ( Fill, H; Hossfeld, DK; Leb, G; Samonigg, H; Spehn, J, 1988) |
| "Nine patients with thyroid cancer were treated with reserpine in an attempt to reduce radiation exposure to the salivary glands from 100-150 mCi doses of I-131 therapy to thyroid remnants or metastases." | ( Levy, HA; Park, CH, 1987) |
| "Patients with thyroid cancer benefit from treatment with exogenous thyroid hormone for two reasons: it provides adequate levels of thyroid hormone to peripheral tissues, and it reduces the level of thyrotropin, which may be an important growth factor in patients with differentiated malignant neoplasms." | ( Dunn, JT, 1986) |
| "In patients with thyroid cancer, subjected to thyroidectomy and then thyroid hormone replacement therapy, the possible development of pseudotumor cerebri syndrome should be considered and differentiated from CNS symptoms due to brain metastases." | ( De Rosa, M; Lombardi, G; Panza, N; Salvatore, M, 1985) |
| "Eleven patients with metastatic thyroid cancer received combination chemotherapy with doxorubicin, bleomycin, vincristine, and melphalan." | ( Brown, L; Bukowski, RM; Groppe, CW; Purvis, J; Weick, JK, 1983) |
| "Fifteen patients with differentiated thyroid cancer were examined following 131I thyroid ablation, of these seven were examined after radio-iodine therapy to disseminated neck cancer." | ( Holub, V; Nĕmec, J; Pohunková, D; Röhling, S; Zamrazil, V, 1984) |
| "In some diseases, as in the treatment of thyroid carcinoma, suppression of TSH secretion and simultaneous substitution of the thyroid hormone deficit are essential." | ( Pfannenstiel, P, 1980) |
| "Nine patients with well-differentiated thyroid cancer aged 9-20 years were treated by thyroidectomy and subsequent irradiation with radioactive iodine." | ( Anger, K; Feine, U, 1983) |
| "In patients treated for thyroid cancer the damage to the salivary glands was revealed by an increase in TPA and amylase serum levels, dependent on the dose of 131-Iodine administered." | ( Becciolini, A; Lanini, A; Porciani, S, 1994) |
| "To determine whether heat-treated thyroid cancer cells augment the susceptibility of target cells to lysis by autologous lymphokine-activated killer cells." | ( Fujieda, S; Hoshino, T; Noda, I; Saito, H; Yagita, M, 1995) |
| "The susceptibility of heat-treated thyroid cancer cells to lysis by autologous and allogeneic lymphokine-activated killer cells was significantly greater than that of untreated tumor cells." | ( Fujieda, S; Hoshino, T; Noda, I; Saito, H; Yagita, M, 1995) |
| "In a study of 136 differentiated thyroid cancer patients referred for radioiodine therapy since January 1991, it was observed that 80 patients had metastatic disease." | ( Desai, KB; Mehta, MN; Samuel, AM, 1994) |
| "Further, thyroid cancer cells incubated with SW, as compared with nontreated tumor cells, showed much higher susceptibility to LAK killing." | ( Fujieda, S; Hoshino, T; Noda, I; Saito, H; Yagita, M, 1994) |
| "Patients with thyroid cancer and concomitant secondary hypothyroidism are particularly difficult to treat because of their inability to elevate endogenous TSH and the limitations of bTSH administration." | ( Ladenson, PW; Ringel, MD, 1996) |
| "The ideal therapy for differentiated thyroid cancer is uncertain." | ( Ain, KB; Bigos, ST; Brierley, JD; Cooper, DS; Haugen, BR; Ho, M; Klein, I; Ladenson, PW; Maxon, HR; Robbins, J; Ross, DS; Sherman, SI; Specker, B; Sperling, M; Taylor, T, 1998) |
| "Measurement of iodide uptake by thyroid cancer cells is the cornerstone of the follow-up and treatment of patients with thyroid cancer." | ( Arturi, F; Bidart, JM; Caillou, B; Filetti, S; Russo, D; Schlumberger, M, 1999) |
| "Since differentiated thyroid cancer has an excellent prognosis, reduction of long-term side effects of high-dose radioiodine treatment (HD-RIT), i." | ( Bohuslavizki, KH; Buchert, R; Clausen, M; Jenicke, L; Klutmann, S; Kröger, S; Mester, J, 1999) |
| "For the treatment of differentiated thyroid cancer, surgery, radioiodide therapy, and thyrotropin-suppressive thyroxine application represent established therapeutic measures of proven efficiency, affording a good prognosis for this disease." | ( Köhrle, J; Schmutzler, C, 2000) |
| "Poorly differentiated and anaplastic thyroid cancers are aggressive and usually fatal neoplasms, despite aggressive treatment." | ( Burman, KD; Chen, X; Greenberg, M; Hayre, N; Priebat, D; Ringel, MD; Saji, M; Suzuki, K, 2000) |
| "Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment." | ( Abbruzzese, A; Caraglia, M; Ciccarelli, A; Fonderico, F; Lupoli, G; Martignetti, A; Nuzzo, V; Vitale, G, 2001) |
| "1) an increased frequency of parathyroid adenoma was found in BC patients with mildly aggressive neoplastic disease; 2) in BC patients with no evidence of primary hyperparathyroidism mean serum PTH and calcium concentrations were significantly greater than in healthy controls and in patients with thyroid carcinoma; and 3) this finding was unrelated to clinical staging or anti-tumor therapy." | ( Conte, PF; Fierabracci, P; Giani, C; Marcocci, C; Miccoli, P; Pinchera, A; Vignali, E; Zaccagnini, M, 2001) |
| "Treatment with 131I for differentiated thyroid cancer may give a follicle-damaging radiation dose to the ovaries." | ( Bencivelli, W; Ceccarelli, C; Morciano, D; Pacini, F; Pinchera, A, 2001) |
| "In 15 patients with advanced thyroid cancer, whose cancer foci did not concentrate radioiodine, 13-cis retinoic acid (Roaccutan) was given for 6 weeks before radioiodine treatment." | ( Handkiewicz-Junak, D; Jarzab, B; Roskosz, J; Turska, M; Wygoda, Z, 2001) |
| "Pregnant women treated for thyroid cancer needed to have optimized their suppressive therapy by increasing the dose of thyroxine by 26% at the first trimester, 27% at the second and 38% at the last one." | ( Czech, W; Debski, R; Gietka-Czernel, M; Jastrzebska, H; Lewartowska, A; Zgliczyński, S, 2001) |
| "Anaplastic thyroid cancer (ATC) does not respond well to any treatment and is one of the most aggressive of all human cancers." | ( Bauer, AJ; Doniparthi, NK; Francis, GL; Patel, A; Ringel, MD; Saji, M; Terrell, R; Tuttle, RM, 2002) |
| "The incidence and treatment of thyroid carcinoma is discussed and the importance of fine needle aspiration of thyroid nodules and the recognition of iodine containing radiographic contrast media in the causation of iodine induced thyrotoxicosis is highlighted." | ( Lazarus, JH; Morse, RE; Owen, PJ, 2003) |
| "Treatment of differentiated thyroid cancer is a success of modern medicine with the use of radioiodine ((131)I)." | ( Christian, JA; Cook, GJ; Harmer, C, 2003) |
| "In the treatment of thyroid cancer the uptake of iodide is essential." | ( Romijn, HA; Schröder-van der Elst, JP; Smit, JW; van der Heide, D, 2003) |
| "In poorly differentiated thyroid cancer, molecular characteristics are reported to be lost such as to cause insensitivity of the tumor to radiometabolic therapy." | ( Arena, K; Boccuzzi, G; Brignardello, E; Catalano, MG; Fortunati, N; Piovesan, A, 2004) |
| "In most patients with thyroid cancer being prepared for (131)I imaging or therapy, a TSH level exceeding 30 micro IU/mL can be achieved by withdrawal of thyroid hormone therapy for 1-3 wk." | ( Bekker, S; Clutter, WE; Grigsby, PW; Moley, JF; Siegel, BA, 2004) |
| "Some thyroid cancers are or become dedifferentiated, and they become refractory to efficacy-proven conventional therapies such as radioiodine ablation therapy and thyrotropin (TSH)-suppressive therapy." | ( Clark, OH; Park, JW, 2004) |
| "Aggressive thyroid cancer frequently needs multimodal adjuvant therapy." | ( Buescu, A; Carvalho, DP; Coelho, SM; Corbo, R; Vaisman, M, 2004) |
| "Patients with differentiated thyroid cancer are often treated transiently with T(3) in preparation for radioactive iodine (RAI) therapy." | ( Arafah, BM; Nasrallah, MP; Serhal, DI, 2004) |
| "Poorly differentiated, metastatic thyroid cancer is difficult to treat." | ( Baumbusch, MA; Haugen, BR; Hays, WR; Hershman, JM; Klopper, JP; Sharma, V, 2004) |
| "Treatment of patients with thyroid cancer is usually successful, and most patients are cured of the disease." | ( Fagin, JA, 2004) |
| "Medullary thyroid cancer is frequently an aggressive form of carcinoma for which there are currently no effective forms of systemic therapy." | ( Asa, SL; Dackiw, A; Ezzat, S; Huang, P, 2005) |
| "Finally, unlike differentiated thyroid cancer, there is no known effective systemic therapy for MTC." | ( Moley, JF; Quayle, FJ, 2005) |
| "Anaplastic thyroid cancer is one of the most aggressive human malignancies and the outcomes of conventional therapy have been far from satisfactory." | ( Hirakawa, K; Ishikawa, T; Nobuhara, Y; Ogisawa, K; Onoda, N; Takashima, T; Yamasaki, M; Yamashita, Y, 2005) |
| "Radioiodine-negative thyroid cancer presents diagnostic and therapeutic difficulties, warranting the implementation of new imaging and treatment strategies." | ( Andreae, F; Angelberger, P; Dudczak, R; Leimer, M; Li, S; Rodrigues, M; Traub-Weidinger, T; Virgolini, I, 2005) |
| "UTC constitutes almost 10% of thyroid cancers and shows a very poor response to chemotherapy." | ( Al-Watban, FA; Zhang, XY, 2005) |
| "In contrast to papillary and follicular thyroid cancer, medullary thyroid cancer (MTC) remains difficult to treat due to its unresponsiveness to radioiodine therapy and its limited responsiveness to chemo- and radiotherapy." | ( Baker, CH; Cengic, N; Göke, B; Morris, JC; Schütz, M; Spitzweg, C, 2005) |
| "Recovery of iodide uptake in thyroid cancer cells by means of obtaining the functional expression of the sodium/iodide symporter (NIS) represents an innovative strategy for the treatment of poorly differentiated thyroid cancer." | ( Arturi, F; Celano, M; Ferretti, E; Filetti, S; Gulino, A; Mattei, T; Presta, I; Russo, D; Scarpelli, D; Scipioni, A; Tosi, E, 2005) |
| "After total thyroidectomy of thyroid cancer, 36 cases were subjected to I-131 treatment 64 times." | ( Akaki, S; Fujie, S; Himei, K; Kanazawa, S; Katsui, K; Okumura, Y; Sato, S; Takemoto, M, 2005) |
| "Treating thyroid cancer cell lines with a new ILK inhibitor, QLT0267, inhibited epidermal growth factor-induced phosphorylation of AKT, inhibited cell growth, and induced apoptosis in the NPA187, DRO, and K4 cell lines." | ( Bekele, BN; Dakak Yazici, Y; El-Naggar, A; Jasser, SA; Kim, S; Mandal, M; Mills, GB; Myers, JN; Schiff, BA; Yigitbasi, OG; Younes, MN, 2005) |
| "We treated 1 papillary and 3 follicular thyroid cancer cell lines with VA (0." | ( Chung, WY; Clark, OH; Duh, QY; Kebebew, E; Shen, WT; Wong, MG; Wong, TS, 2005) |
| "In conclusion, these data indicate that thyroid neoplasms observed in the nelfinavir-treated rats were secondary to thyroid hormone imbalance." | ( Burns-Naas, LA; Capen, CC; Chen, M; Cook, JC; Evering, W; Furman, G; Gasser, R; Ivett, JL; Jessen, B; McClain, RM; Ryan, TE; Shetty, B; Stevens, G; Theiss, JC; Webber, S; Wu, E; Zorbas, M, 2005) |
| "181 patients with well-differentiated thyroid cancer were surveyed using a thyroid-specific QOL-thyroid survey at three times throughout the study: prior to T4 withdrawal, after the 3-week withdrawal period, and 4 weeks after resuming T3/T4 combination therapy." | ( Davids, T; Eski, S; Freeman, JL; Walfish, PG; Witterick, IJ, 2006) |
| "Differentiated thyroid cancer and hyperthyroidism are treated with radioiodine." | ( Agote Robertson, M; Dagrosa, MA; Finochietto, P; Franco, MC; Gamba, CA; Juvenal, GJ; Pisarev, MA; Poderoso, JJ; Viaggi, ME, 2006) |
| "Although thyroid cancer was about 4 times the incidence in the general population, this may be attributed to a high level of detection while work-up, treating and following the parathyroid disease." | ( Cinamon, U; Turcotte, RE, 2006) |
| "Most thyroid cancers are slow-growing, easily treatable tumors with an excellent prognosis after surgical resection and targeted medical therapy." | ( Angelos, P; Sturgeon, C, 2006) |
| "Fifteen patients with differentiated thyroid cancers and continued international normalized ratio (INR)-adjusted therapy with coumarin derivates were included in this retrospective analysis." | ( Biersack, HJ; Bucerius, J; Joe, AY; Palmedo, H; Reinhardt, MJ, 2006) |
| "Most thyroid cancers are slow-growing, easily treatable tumors with an excellent prognosis after surgical resection and targeted medical therapy." | ( Angelos, P; Sturgeon, C, 2006) |
| "In patients affected by differentiated thyroid cancer (DTC), the lacking of 131Iodine trapping by metastatic tissue does not allow 131Iodine whole body scintigraphy to visualize matastatic spread as well as the use of 131Iodine therapy to cure such metastatic spread." | ( Ambrosini, V; Banti, E; Carpi, A; Fanti, S; Farsad, M; Franchi, R; Muzzio, P; Nanni, C; Rampin, L; Rubello, D, 2006) |
| "Patients with undifferentiated thyroid cancer are in desperate need of new therapeutic strategies because common protocols of therapy usually fail." | ( Burchert, A; Dietrich, C; Gläser, S; Hoffmann, S; Lingelbach, S; Müller, H; Rothmund, M; Wunderlich, A; Zielke, A, 2006) |
| "In vitro, thyroid cancer cell lines responded to RA with reduced proliferation, ranging from 26 to 34% after 2 weeks of treatment and with up to 80% reduced secretion of VEGF." | ( Celik, I; Hofbauer, LC; Hoffmann, S; Lingelbach, S; Ramaswamy, A; Rockenstein, A; Wunderlich, A; Zielke, A, 2007) |
| "Of the 94 cases of anaplastic thyroid cancers diagnosed and treated in British Columbia, Canada over a 20-year period (1984-2004), 32 cases (34%) had adequate archival tissue available for evaluation." | ( Bugis, S; Filipenko, D; Gilks, B; Hay, J; Huntsman, D; Masoudi, H; Niblock, P; Rajput, A; Turbin, D; Wiseman, SM, 2007) |
| "Ten patients with differentiated thyroid cancer were enrolled in an open-label, phase II trial of oral rosiglitazone treatment (4 mg daily for 1 week, then 8 mg daily for 7 weeks)." | ( Clark, OH; Duh, QY; Greenspan, FS; Kebebew, E; Lindsay, S; Morita, E; Peng, M; Reiff, E; Treseler, P; Woeber, KA, 2006) |
| "They had dedifferentiated thyroid cancers (DTC) (four follicular, five papillary, two oxyphilic) and were selected for treatment with ATRA (1." | ( Jia, S; Li, B; Liu, Y; Lu, H; Wang, Z; Zhang, Y; Zhu, C, 2007) |
| "After total thyroidectomy all thyroid cancer patients require lifelong treatment with thyroid hormones; the treatment of choice is synthetic levothyroxine (LT4)." | ( Alagona, C; Alagona, G; Cianci, M; Maiorana, R; Paola, RD; Pezzino, V; Regalbuto, C; Sapienza, S; Squatrito, S, 2007) |
| "Anaplastic thyroid cancer (ATC) is extremely aggressive, and no effective treatment is available." | ( Chaplin, D; Pan, J; She, M; Sun, L; Yang, H; Yeung, SC, 2007) |
| "One papillary thyroid cancer cell line, K1 cells and two anaplastic thyroid cancer cell lines, TTA1 and TTA2 cells were treated with forskolin, which directly activates adenyl cyclase to raise the level of intracellular cAMP." | ( Bando, H; Fujiwara, M; Hara, H; Ito, K; Kamma, H; Matsumoto, H; Uchida, K; Ueno, E; Yano, Y; Yashiro, T, 2007) |
| "Undifferentiated thyroid cancer (UTC) is a very aggressive tumor with no effective treatment, since it lacks iodine uptake and does not respond to radio or chemotherapy." | ( Dagrosa, MA; Juvenal, GJ; Pisarev, MA, 2007) |
| "After the initial thyroid cancer treatment, the detection of likely recurrences and/or metastases is made through the measurement of serum markers determinations and diagnostic image procedures." | ( Caetano, R; Coeli, CM; Kuba, VM; Vaisman, M, 2007) |
| "Anaplastic thyroid cancer (ATC) is often inoperable and chemotherapy and radiotherapy are the main treatments." | ( Antonelli, A; Barani, L; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Marchetti, I; Materazzi, G; Miccoli, P, 2008) |
| "Anaplastic thyroid cancer cell lines DRO, ARO, and FRO were treated with LGD1069 in vitro." | ( Berenz, A; Bissonnette, RP; Haugen, BR; Hays, WR; Janssen, J; Klopper, JP; Pugazhenthi, U; Sharma, V; Singh, M, 2008) |
| "The 10-yr survival of differentiated thyroid cancer is about 76-93%, and at least 10% of patients manifest tumor persistence or recurrence, depending on their disease stage, after initial therapy, which typically includes total thyroidectomy and (131)I ablation." | ( Kloos, RT, 2008) |
| "Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeutic options." | ( Bycott, P; Cohen, EE; Cohen, RB; Forastiere, AA; Kane, MA; Kies, MS; Kim, S; Liau, KF; Rosen, LS; Shalinsky, DR; Sherman, E; Tortorici, M; Vokes, EE; Worden, FP, 2008) |
| "Anaplastic thyroid cancer (ATC) is often unoperable and chemotherapy and radiotherapy are the main treatments." | ( Antonelli, A; Basolo, F; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Marchetti, I; Materazzi, G; Miccoli, P; Ugolini, C, 2008) |
| "Although thyroid cancers are readily treatable with surgery and radioactive iodine, there are problems in managing recurring, as well as locally advanced, thyroid cancer." | ( Crist, HS; Fedok, F; Goldenberg, D; McLaughlin, PJ; Zagon, IS, 2008) |
| "A subset of patients with papillary thyroid cancer (PTC) present with aggressive disease that is refractory to conventional treatment." | ( Abramson, MA; Bertagnolli, MM; Donner, DB; Lin, CI; Moore, FD; Ruan, DT; Whang, EE, 2009) |
| "In the treatment of differentiated thyroid cancer, requiring long-term check-ups and visits as well as administration of high doses of levothyroxine (TSH - thyroid-stimulating hormone - suppression), also in elderly patients, telemedicine seems particularly indicated." | ( Gibelli, B; Gibelli, G; Nani, F, 2008) |
| "Poorly differentiated and anaplastic thyroid cancers are aggressive malignancies unresponsive to standard treatments." | ( Bufo, P; Cignarelli, M; Costantino, E; Fabiano, A; Farese, A; Landriscina, M; Maddalena, F; Piscazzi, A, 2009) |
| "Twenty patients with differentiated thyroid cancer were enrolled in an open-label, phase II trial of oral rosiglitazone treatment (4 mg daily for 1 week, then 8 mg daily for 7 weeks)." | ( Clark, OH; Greenspan, FS; Hawkins, R; Kebebew, E; Lindsay, S; Woeber, KA, 2009) |
| "Differentiated thyroid cancers and their metastases frequently exhibit reduced iodide uptake, impacting on the efficacy of radioiodine ablation therapy." | ( Boelaert, K; Eggo, MC; Fong, JC; Franklyn, JA; James, SR; Lewy, GD; McCabe, CJ; Read, ML; Smith, VE; Turnell, AS; Watkins, RJ; Watkinson, JC, 2009) |
| "The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed." | ( Busaidy, N; Hong, D; Kurzrock, R; Markman, M; Naing, A; Ng, C; Sherman, SI; Tse, S; Tsimberidou, AM; Vaklavas, C; Wen, S; Wheler, J, 2009) |
| "Patients with advanced thyroid cancer treated on phase I clinical trials had high rates of partial response and prolonged stable disease." | ( Busaidy, N; Hong, D; Kurzrock, R; Markman, M; Naing, A; Ng, C; Sherman, SI; Tse, S; Tsimberidou, AM; Vaklavas, C; Wen, S; Wheler, J, 2009) |
| "Although most patients with papillary thyroid cancer (PTC) have favorable outcomes, some have advanced PTC that is refractory to external beam radiation and systemic chemotherapy." | ( Carothers, AM; Delaine, T; Donner, DB; Jiang, X; Leffler, H; Lin, CI; Moore, FD; Nilsson, UJ; Nose, V; Price, BD; Ruan, DT; Whang, EE, 2009) |
| "Differentiated thyroid cancer (DTC) is the most common endocrine malignancy with the highest mortality although with appropriate treatment has a good long-term prognosis and cure rate." | ( Ambrosetti, MC; Colato, C; Dardano, A; Ferdeghini, M; Monzani, F, 2009) |
| "Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine and thyrotropin-suppressive thyroid hormone treatment." | ( Schlumberger, M; Sherman, SI, 2009) |
| "The standard treatment of papillary thyroid cancer with a diameter >1 cm is thyroidectomy combined with a modified neck-dissection of the central (perithyroideal, prelaryngeal and tracheo-esophageal) lymph nodes and a consecutive radiation." | ( Kraft, K; Schencking, M, 2010) |
| "Primary therapy of thyroid cancer is an adequate surgery: total thyreoidectomy and, if necessary, lymph node dissection or limited surgery in selected cases." | ( Konrády, A, 2011) |
| "Current treatments for thyroid cancer, such as surgery or radioactive iodine therapy, often require patients to be on lifelong thyroid hormone replacement therapy and given the significant recurrence rates of thyroid cancer, new preventive modalities are needed." | ( Geliebter, J; George, A; Rajoria, S; Schantz, SP; Shanmugam, A; Suriano, R; Tiwari, RK, 2011) |
| "Moreover, treatment of WRO and FRO thyroid cancer cell lines with the deacetylase inhibitor tricostatin A (TSA) or suberoylanilide hydroxamic acid (SAHA) increases levels of acetylated H3 histone to periostin promoter however, unpredictably, reduces periostin mRNA levels." | ( Damante, G; Frasca, F; Passon, N; Puppin, C; Tomaciello, S; Tomay, F; Vigneri, R, 2011) |
| "A 53-year-old woman with papillary thyroid cancer stage III (T1N1aM0) who had undergone total thyroidectomy and 150 mCi of radioiodine treatment for remnant ablation was found to have focal intense radioiodine accumulation in the left lung field by WBS, suggestive of pulmonary metastasis, at 5 days after I-131 administration." | ( Ahn, BC; Kim, C; Lee, J; Lee, SW, 2011) |
| "Patients with advanced thyroid cancer may benefit from l-thyroxine treatment at doses that suppress serum TSH level, local treatment interventions, and radioiodine therapy." | ( Schlumberger, M; Sherman, SI, 2012) |
| "We report a case of metastatic thyroid cancer presenting with severe hyponatremia in association with hypothyroidism induced by pretreatment of I(131) therapy, such as a low-iodine diet and withdrawal of thyroid hormone." | ( Nozu, T; Ohira, M; Okumura, T; Yoshida, Y, 2011) |
| "Anaplastic thyroid cancer (ATC), a subtype of thyroid cancer (TC), fails to respond to conventional TC treatment." | ( Arndt, T; Bartsch, DK; Brendel, C; Fischer, M; Greene, BH; Hinterseher, U; Hoffmann, S; Ramaswamy, A; Roth, S; Wunderlich, A, 2012) |
| "Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations." | ( Bollag, G; Chakravarty, D; Fagin, JA; Ghossein, R; Knauf, JA; Kolesnick, R; Larson, SM; Liao, XH; Refetoff, S; Rosen, N; Ryder, M; Santos, E; Thin, TH; West, BL; Zanzonico, P, 2011) |
| "Differentiated thyroid cancers (DTCs) are commonly treated by total thyroidectomy followed by I-131 radioiodine ablation to eradicate any residual thyroid tissue and to detect any metastatic lesions on post-treatment whole body scans (TxWBS)." | ( Ito, S; Iwano, S; Kato, K; Naganawa, S; Tsuchiya, K, 2012) |
| "To effectively treat differentiated thyroid cancer (DTC) with radioiodine (RAI) it is necessary to raise serum thyrotropin (TSH) levels either endogenously by thyroid hormone withdrawal (THW) or exogenously by administration of recombinant human TSH (rhTSH)." | ( Burman, KD; Jonklaas, J; Klubo-Gwiezdzinska, J; Mete, M; Van Nostrand, D; Wartofsky, L, 2012) |
| "The two thyroid cancer cell lines 8505C and TPC1, under adherent culture conditions, were treated with berberine and analyzed for changes in cell growth, cell cycle duration, and degree of apoptosis." | ( Bae, J; Jee, HG; Kim, JB; Lee, KE; Park, KS; Park, SY; Youn, YK, 2012) |
| "Patients with anaplastic thyroid cancer showed poor prognosis despite multimodality treatment." | ( Cho, BC; Cho, JY; Chung, WY; Hong, YK; Kang, SW; Keum, KC; Kim, JH; Lim, SM; Nam, KH; Park, CS; Shin, SJ, 2012) |
| "A female papillary thyroid cancer patient with diffuse micronodular pulmonary metastases was confirmed only by post radioactive iodine (RAI) therapy whole body scan (RxWBS)." | ( Cheng, X; Liang, ZY; Lin, YS; Qiu, LH, 2012) |
| "An 80-year-old male with recurrent thyroid cancer and a percutaneous endoscopic gastrostomy (PEG) tube in situ was referred for radioiodine therapy and was administered 5510 MBq I-131 sodium iodide intravenously." | ( Clauss, RP; Hinton, PJ; Kilfeather, SA; Scuffham, JW; Wood, KA, 2012) |
| "In this study, three human thyroid cancer cells (B-CPAP, CGTH-W-1, ML-1) were treated with estrogen alone or estrogen and anti-estrogens (fulvestrant and 3,3'-diindolylmethane, a natural dietary compound) for 24 hours." | ( Geliebter, J; George, AL; Kamat, A; Rajoria, S; Schantz, SP; Suriano, R; Tiwari, RK, 2012) |
| "Implication of TSPO in the thyroid cancer cell response to oxidative stress suggested its potential role in the regulation of thyroid cancer cell response to treatment with radioiodine and warrants further investigation." | ( Bauer, A; Burman, KD; Costello, J; Hardwick, MJ; Jensen, K; Klubo-Gwiezdzinska, J; Patel, A; Vasko, VV; Wartofsky, L, 2012) |
| "Anaplastic thyroid cancer is an extremely aggressive disease resistant to radioiodine treatment because of loss of sodium iodide symporter (NIS) expression." | ( Eberhardt, NL; Madde, P; McDonough, SJ; McIver, B; Morris, JC; Myers, RM; Peng, KW; Reddi, HV; Russell, SJ; Trujillo, MA, 2012) |
| "In differentiated thyroid cancer (DTC) nuclear medicine is able to cover the spectrum from diagnosis and treatment to follow up keeping patient's management in one institution." | ( Kohlfürst, S, 2012) |
| "Patients with differentiated thyroid cancer (DTC) who have a suspicious recurrent or persistent disease based on an elevated serum thyroglobulin (Tg) or Tg antibodies (TgAb) are usually referred for empiric radioiodine ((131)I) administration to localize and treat the disease." | ( Al Ghuzlan, A; Baudin, E; Bidault, F; Borget, I; Chougnet, C; Déandreis, D; El Bez, I; Elleuch, M; Hartl, D; Leboulleux, S; Lumbroso, J; Mirghani, H; Schlumberger, M, 2012) |
| "The 18F-FDG uptake of untreated papillary thyroid carcinoma has an inverse correlation with NIS expression." | ( Baek, CH; Choe, YS; Choi, JY; Jeong, HS; Kim, BT; Lee, KH; Moon, SH; Oh, YL; Son, YI, 2013) |
| "Anaplastic thyroid cancer (ATC) is the most aggressive form of human thyroid cancer, lacking any effective treatment." | ( Asghar, MY; Kemppainen, K; Törnquist, K; Viitanen, T, 2012) |
| "Human thyroid cancer-derived cell lines, TPC-1, were treated with ALA, and changes in NIS mRNA and protein expression were measured." | ( Choi, HJ; Han, JM; Jeon, MJ; Kim, TY; Kim, WB; Kim, WG; Ruiz-Llorente, S; Shong, YK, 2012) |
| "Patients with advanced medullary thyroid cancer (MTC) have poor prognoses and limited treatment options." | ( Brown, RL; Cohen, EE; Nagilla, M, 2012) |
| "Treatment of medullary thyroid cancer is mainly based on surgery." | ( , 2012) |
| "Conventional treatment modalities for thyroid cancer lead to complete remission in only one-third of patients with distant metastases." | ( Karras, S; Krassas, GE; Pontikides, N, 2013) |
| "The papillary thyroid cancer cell lines K1 and W3 and thyroid follicular epithelial cells NTHY-ORI 3-1 were treated with different concentrations of shikonin." | ( Chen, J; Liu, C; Yin, L, 2014) |
| "Due to the increasing incidence of thyroid cancer worldwide, more patients are now receiving postoperative RAI therapy." | ( Choi, HY; Ha, SK; Kim, KH; Kim, SK; Park, HC; Park, SK; Yun, GY, 2014) |
| "Patients with advanced thyroid cancer derived meaningful clinical benefit from additional therapy with a biologic agent following disease progression on front-line targeted therapy." | ( Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM, 2013) |
| "Mice bearing flank anaplastic thyroid cancers (ATC) were daily treated with intraperitoneal injection of PXD101 for 5 days per week." | ( Chou, TC; Huang, YY; Lin, JD; Lin, SF; Wong, RJ, 2013) |
| "PXD101 represses thyroid cancer proliferation and has synergistic effects in combination with doxorubicin and paclitaxel in treating ATC." | ( Chou, TC; Huang, YY; Lin, JD; Lin, SF; Wong, RJ, 2013) |
| "Human thyroid cancer cell lines (8505c, HTh7, BCPAP, and TPC-1) were treated with either 10 μmol/L 5'-azacytidine (Aza) or 10 μmol/L 5-AZA-2'deoxycytidine (DAC) and evaluated for various MAGEA gene expression." | ( Bernasconi, MJ; Cogdill, AP; Gunda, V; Parangi, S; Wargo, JA, 2013) |
| "To quantify the incidence of thyroid cancer after Hodgkin lymphoma (HL) and determine disease characteristics, risk factors, and treatment outcomes." | ( Chen, YH; Marcus, KJ; Michaelson, EM; Ng, AK; Silver, B; Stevenson, MA; Tishler, RB, 2014) |
| "Routine thyroid cancer screening may benefit females treated at a young age and ≥10 years from HL treatment owing to their higher risk, which increases over time." | ( Chen, YH; Marcus, KJ; Michaelson, EM; Ng, AK; Silver, B; Stevenson, MA; Tishler, RB, 2014) |
| "Physicians who treat patients with thyroid cancer should be aware of these data to further assist in their assessment and care." | ( Gardiner, P; Gupta-Lawrence, RL; Hammer, K; Lee, SL; Pearce, EN; Rosen, JE; Saper, RB, 2014) |
| "Recently, the main therapy of medullary thyroid cancer (MTC) is surgical, but by which way there is a poor prognosis with a mean survival of only 5 years." | ( Chen, XY; Duan, LQ; Hou, YL; Hu, XL; Kang, QQ; Li, SL; Peng, ZP; Shu, J; Tang, M, 2014) |
| "Ninety-eight thyroid cancer patients who were treated with RIT using both thyroid hormone withdrawal (THW) and rhTSH were enrolled." | ( Kim, SE; Lee, HY; Lee, SJ; Lee, WW, 2014) |
| "In the follow-up of differentiated thyroid cancer (DTC) after a successful total-near total thyroidectomy and I-131 ablation therapy, anti-thyroglobulin antibodies (anti-Tg) may be persistently or progressively increased in the patients with an undetectable serum thyroglobulin (Tg) level." | ( Aksoy, SY; Aliyev, A; Asa, S; Halac, M; Ozhan, M; Sager, S; Sonmezoglu, K; Uslu, L; Vatankulu, B, 2014) |
| "Ionizing radiation in differentiated thyroid cancer (DTC) patients treated with radioiodine (131-I) produces reactive oxygen species (ROS), which could induce oxidative stress with disturbance of redox balance." | ( Djukic, SM; Jovanovic, MD; Radivojevic, SD; Simonovic, ST; Teodorovic, LC; Vrndic, OB, 2014) |
| "Patients (N = 60) with advanced thyroid cancer of any histology for whom iodine-131 ((131)I) failed to control the disease or (131)I was not appropriate therapy were administered axitinib 5 mg twice daily." | ( Bycott, P; Cohen, EE; Ingrosso, A; Kim, S; Pithavala, YK; Tortorici, M, 2014) |
| "Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine." | ( Ball, DW; Byrd, D; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Tuttle, RM; Waguespack, SG; Wang, TN; Wirth, LJ, 2014) |
| "The treatment of differentiated thyroid cancer refractory to radioactive iodine (RAI) had been hampered by few effective therapies." | ( Colevas, AD; Gruber, JJ, 2015) |
| "Pretreatment thyroid cancer blocks from 18 patients treated with axitinib were collected and genomic DNA was isolated." | ( Carcangiu, ML; Cohen, EE; Greco, A; Joseph, L; Khattri, A; Licitra, L; Lingen, MW; Locati, LD; Nagilla, M; Pelosi, G; Reddy, P; Schechter, RB; Seiwert, TY; Watson, S, 2015) |
| "Anaplastic thyroid cancer (ATC) is one of the most lethal human malignancies that currently has no effective therapy." | ( Boufraqech, M; Boxer, MB; Copland, JA; Davis, S; Kebebew, E; Kiefer, JA; Li, Z; Mehta, A; Shen, M; Smallridge, RC; Tian, Z; Wang, J; Yu, Z; Zhang, L; Zhang, Y, 2015) |
| "Anaplastic thyroid cancer (ATC) is a rare but lethal malignancy without any effective therapy." | ( Aufforth, R; Boufraqech, M; Davis, S; Kebebew, E; Li, Z; Liu-Chittenden, Y; Mehta, A; Patel, D; Rosenberg, A; Shen, M; Ylaya, K; Zhang, L; Zhang, Y, 2015) |
| "We randomized 55 thyroid cancer patients into two groups: 29 patients underwent 5 weeks of half-dose of previous L-T4 treatment (HD group); 26 patients replaced L-T4 with L-T3 for 3 weeks followed by 2 weeks of withdrawal (TW group)." | ( Latina, A; Malandrino, P; Marturano, I; Regalbuto, C; Russo, M; Spadaro, A, 2015) |
| "Medullary thyroid cancer (MTC)-related diarrhea can be debilitating, reduces quality of life (QOL), and may be the only indication for initiating systemic therapy." | ( Busaidy, NL; Cabanillas, ME; Cleeland, C; Dadu, R; Fox, P; Habra, M; Hu, MI; Sherman, SI; Waguespack, SG; Ying, A, 2015) |
| "Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy." | ( Covell, LL; Ganti, AK, 2015) |
| "Routine treatment of thyroid cancer (TC) includes long-term suppression of TSH." | ( Fröhlich, E; Wahl, R, 2016) |
| "131I treatment (tx) of differentiated thyroid cancer (DTC) is associated with hematopoietic toxicity." | ( Bikas, A; Burman, KD; Desale, S; Jensen, K; Mete, M; Patel, A; Van Nostrand, D; Vasko, V; Wartofsky, L, 2016) |
| "The standard treatment for thyroid cancer includes total thyroidectomy with or without radioactive iodine ablation, often followed by thyrotropin suppression therapy." | ( Hawley, ST; Haymart, MR; Papaleontiou, M, 2016) |
| "We created a line of BCPAP papillary thyroid cancer cells resistant to vemurafenib by treating with increasing concentrations of the drug." | ( Bednarczyk, RB; Darzynkiewicz, Z; Geliebter, J; Hanly, EK; Moscatello, AL; Suriano, R; Tiwari, RK; Tuli, NY, 2016) |
| "Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, with no effective treatment currently available." | ( Boufraqech, M; Kebebew, E; Lake, R; Zhang, L, 2016) |
| "We investigated the role of PD-L1 in thyroid cancer with respect to BRAF mutation and MAP kinase pathway activity and the effect of anti PD-L1 antibody therapy on tumor regression and intra-tumoral immune response alone or in combination with BRAF inhibitor (BRAFi)." | ( Amin, S; Brauner, E; Dennett, KV; Freeman, GJ; Gunda, V; Kim, YS; Parangi, S; Vanden Borre, P; Zurakowski, D, 2016) |
| "AMPK is activated in thyroid cancer cell lines, and AICAR treatment further increased AMPK phosphorylation." | ( Andrade, BM; Carvalho, DP; Cazarin, JM; Coelho, RG; Hecht, F, 2016) |
| "Metastatic differentiated thyroid cancer (DTC) is a rare disease that is in the first line treated with iodine-131 radioisotope therapy." | ( Cathomas, R; Kneifel, S; Mischler, K, 2016) |
| "Radioiodide (RAI) therapy of thyroid cancer exploits the relatively selective ability of thyroid cells to transport and accumulate iodide." | ( Bolaender, A; Carrasco, N; Fagin, JA; Ferrandino, G; Ho, AL; Irwin, C; Ishii, N; Knauf, JA; Krishnamoorthy, GP; Larson, SM; Le, M; Montero-Conde, C; Nagarajah, J; Pillarsetty, N; Rosen, N; Saqcena, M; Seshan, V; Weber, WA, 2016) |
| "Treatment of differentiated thyroid cancer consists of surgery followed by radioactive iodine (RAI) ablation of the thyroid remnant, and TSH suppression." | ( Brzostek, T; Kawalec, P; Kózka, M; Malinowska-Lipień, I, 2016) |
| "Mice bearing flank anaplastic thyroid cancer (ATC) were treated with intraperitoneal injections of dinaciclib." | ( Chou, TC; Hsueh, C; Lin, JD; Lin, SF; Wong, RJ, 2017) |
| "In orthotopic thyroid cancer mouse models of 8505c and BCPAP, treatment with the triple drug combination reduced the size of the tumors and showed significantly higher numbers of cells undergoing apoptosis." | ( Amin, S; Brauner, E; Gunda, V; Kim, YS; Letai, A; Parangi, S; Sarosiek, KA; Zhou, Z, 2017) |
| "Human thyroid cancer cell lines TPC-1 (papillary), FTC-133 (follicular), and BHT-101 (anaplastic) were treated with curcumin." | ( Lennartz, K; Schmid, KW; Schwertheim, S; Sheu-Grabellus, SY; Wein, F; Worm, K, 2017) |
| "Treatment options for patients with thyroid cancer that is no longer sensitive to iodine therapy are limited." | ( Brown, SR; Du, Y; Flanagan, L; Flux, G; Gregory, R; Hall, A; Moss, L; Newbold, K; Wadsley, J, 2017) |
| "The rate of thyroid cancer is increasing in France, as well as concerns about overdiagnosis and treatment." | ( Bigorgne, C; Cuerq, A; Fagot-Campagna, A; Fery-Lemonnier, E; Leenhardt, L; Mathonnet, M; Millat, B; Russ, G; Thalabard, JC; Tresallet, C; Tuppin, P, 2017) |
| "Medullary thyroid cancer (MTC) is a tumor highly resistant to chemo- and radiotherapy." | ( Borghi, MO; Cantone, MC; Caraglia, M; Di Blasio, AM; Dicitore, A; Gaudenzi, G; Gelmini, G; Gentilini, D; Grassi, ES; Hofland, LJ; Misso, G; Pepe, D; Persani, L; Vitale, G, 2017) |
| "A subset of patients with papillary thyroid cancer present with aggressive disease that is refractory to conventional treatment." | ( Bae, SK; Ha, TK; Jung, I; Kim, ME; Lee, JS, 2017) |
| "Anaplastic thyroid cancer is one of the most lethal diseases, and a curative therapy does not exist." | ( Argenziano, M; Berta, L; Bussolati, B; Castellano, I; Catalano, MG; Cavalli, R; Frairia, R; Grange, C; Marano, F; Mastrocola, R; Rinella, L, 2017) |
| "Dedifferentiated papillary thyroid cancer (DePTC) is characterized by aggressive growth, recurrence, distant metastasis, and resistance to radioactive iodine (RAI) therapy." | ( Chen, H; Chen, Y; Jiang, N; Li, B; Lin, X; Liu, S; Liu, X; Luo, D; Luo, Q; Qiu, M; Wang, J; Yan, X; Yang, D; Yi, H; Zhang, H; Zhang, L, 2017) |
| "Currently, therapy for thyroid cancer mainly involves surgery and radioiodine therapy." | ( Li, S; Sheng, S; Sun, H; Zhang, D, 2017) |
| "Anaplastic thyroid cancer (ATC) has a very poor prognosis due to its aggressive nature and resistance to conventional treatment." | ( Choi, EJ; Jang, IH; Kim, DK; Kim, HY; Kim, JH; Kim, SJ; Kwon, YW; Lee, JC; Lee, SI; Seo, EJ; Shong, M, 2017) |
| "TSH-suppression is a therapy for thyroid cancer management, but it may lead to adverse effects, which should be balanced with its benefits." | ( De Melo, TG; Fernandes, AM; Ficher, E; Montali Da Assumpção, LV; Monte Alegre, S; Souza, AL; Zantut-Wittmann, DE, 2018) |
| "Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite systemic cytotoxic chemotherapy." | ( Busaidy, NL; Cabanillas, ME; Dadu, R; Ferrarotto, R; Gross, N; Gule-Monroe, M; Habra, MA; Hess, KR; Iyer, PC; Williams, MD; Zafereo, M, 2018) |
| "The value of Ga-DOTATATE in medullary thyroid cancer is being investigated and is currently recommended for use when treatment with somatostatin analogs is an option." | ( Grewal, RK; Mahajan, S; Shaha, A, 2018) |
| "New insights in thyroid cancer biology propelled the development of targeted therapies as salvage treatment for radioiodine-refractory differentiated thyroid cancer (RR-DTC), and the tyrosine kinase inhibitor (TKI) lenvatinib has recently become available as a new line of therapy for RR-DTC." | ( Akaishi, J; Hames, KY; Ito, K; Kitagawa, W; Masaki, C; Matsuzu, K; Nagahama, M; Ogimi, Y; Ohkuwa, K; Sugino, K; Suzuki, A; Tomoda, C; Uruno, T, 2018) |
| "However, thyroid cancers that are progressive despite standard-of-care therapy appear to only rarely express PPFP." | ( Caoili, EM; Giordano, TJ; Haugen, BR; Koenig, RJ; Shah, MH; Sherman, SI, 2018) |
| "Radioresistance of thyroid cancer often leads to therapy failure and cancer-related death." | ( Chen, P; Li, PD; Li, Y; Liu, T; Ma, C; Peng, X; Zhang, WJ; Zou, ZW, 2018) |
| "LncRNA PTCSC3 is a tumor suppressor in thyroid cancer, and its role in drug resistance of anaplastic thyroid cancer (ATC) to chemotherapy drug doxorubicin was investigated in this study." | ( Fan, YX; Geng, ZS; Gu, L; Jia, M; Liu, Y; Liu, Z; Lu, XB; Wang, XM; Yuan, QL, 2018) |
| "Although most thyroid cancer can be cured with surgery, radioactive iodine, and/or chemotherapy, thyroid cancers still recur and may become chemoresistant." | ( Chan, ABW; Chen, GG; Guo, W; Li, MY; Liu, SYW; Liu, Z; Luo, DC; Ng, EKW; Ng, SK; Ren, J; Tong, MCF; van Hasselt, CA; Vlantis, AC; Wang, S; Wu, J; Xue, L, 2018) |
| "Anaplastic thyroid cancer cells were treated with 0-60 mM metformin for 24, 48 and 72 h." | ( Azizi, F; Hedayati, M; Mohammadi-Yeganeh, S; Nozhat, Z; Zarkesh, M, 2018) |
| "Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite aggressive multimodal therapy." | ( Alessandrini, A; Amin, S; Ashry, T; Freeman, GJ; Gigliotti, B; Gunda, V; McCarthy, M; Ndishabandi, D; Parangi, S; Zhou, Z, 2018) |
| "Objective Many thyroid cancer patients are exposed to long-term thyroid-stimulating hormone (TSH) suppression, often as lifetime treatment, and are consequently at risk for cardiovascular disease." | ( Cho, B; Guallar, E; Lim, H; Park, JH; Park, Y; Shin, DW; Song, SO; Suh, B; Yun, JM, 2019) |
| "The prognosis and treatment of thyroid cancer depends on the type and stage of the disease." | ( Ashizawa, K; Ihara, M; Kudo, T; Shichijo, K, 2019) |
| "Patients with anaplastic thyroid cancer (ATC) have an extremely poor prognosis despite multimodal therapy with surgery and chemoradiation." | ( Alessandrini, A; Amin, S; Ashry, T; Freeman, GJ; Gigliotti, B; Gunda, V; Lee, KE; McCarthy, M; Ndishabandi, D; Parangi, S; Stork, T; Wirth, L; Zhou, Z, 2019) |
| "Using a panel of thyroid cancer cell lines expressing clinically relevant mutations in BRAF or RAS, which were previously developed to be resistant to dasatinib, we identified a switch to a more invasive phenotype in the BRAF-mutant cells as a potential therapy escape mechanism." | ( Clark, EG; Kellett, MD; Kessler, BE; Kim, J; Mishall, KM; Pozdeyev, N; Pugazhenthi, U; Schweppe, RE; Tan, AC, 2019) |
| "Anaplastic thyroid cancer (ATC) is the most aggressive human thyroid malignancy, characterized by dedifferentiation and resistance to radioiodine therapy." | ( Chen, G; Dang, Y; Fang, R; Gao, X; Guo, Q; Jiao, C; Li, K; Li, L; Li, X; Moses, R; Pan, L; Qiao, S; Shi, K; Wang, Q; Wang, X; Wu, W; Xiao, J; Xu, S; Yuan, L; Zhang, L; Zhang, P; Zuo, D, 2020) |
| "Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options." | ( Cheng, SY; Lee, WK; Park, S; Zhu, X, 2019) |
| "Recent thyroid cancer guidelines found it reasonable to use local therapies during treatment with tyrosine kinase inhibitors (TKIs) in selected patients with oligoprogressive disease, namely, in the presence of a single progressing lesion in an otherwise TKI-responsive metastatic cancer." | ( Gambale, C; Luongo, C; Porcelli, T; Salvatore, D; Sessa, F, 2019) |
| "Patients with medullary thyroid cancer (MTC) are often diagnosed with spread tumour disease and the development of better systemic treatment options for these patients is important." | ( Forssell-Aronsson, E; Montelius, M; Nilsson, O; Sandblom, V; Shubbar, E; Spetz, J; Ståhl, I; Swanpalmer, J, 2019) |
| "Medical records of 79 medullary thyroid cancer patients treated with vandetanib at our center were analysed." | ( Agate, L; Bottici, V; Cappagli, V; Ciampi, R; Elisei, R; Matrone, A; Molinaro, E; Piaggi, P; Ramone, T; Romei, C; Tacito, A; Valerio, L; Viola, D, 2020) |
| "Using eight established thyroid cancer cell lines, we created an efficient and cost-effective 3D culture system that can enhance our understanding of in vivo treatment response." | ( Bauer, JA; Bergdorf, KN; Byon, SY; Jones, CY; Lee, MA; Phifer, CJ; Sawyer, LM; Weiss, VL, 2020) |
| "Standard treatment of differentiated thyroid cancer includes total thyroidectomy and high-dose Radioactive Iodine Therapy (RIT) for ablation of remnant thyroid tissue." | ( Altun, GD; Ergulen, A; Muratli, A; Serim, BD; Torun, N, 2019) |
| "Patients with thyroid cancer are often assumed to have no quality of life (QOL) impairments after treatment because of thyroid cancer's good prognosis." | ( Büttner, M; Hinz, A; Musholt, TJ; Singer, S, 2020) |
| "Low-risk differentiated thyroid cancer (DTC) is currently rarely treated with radioiodine (131I) to ablate the postoperative remnant." | ( Agate, L; Basolo, F; Elisei, R; Faranda, A; Gambale, C; Latrofa, F; Matrone, A; Molinaro, E; Piaggi, P; Stefani Donati, D; Torregrossa, L; Viola, D, 2020) |
| "Since patients with medullary thyroid cancer (MTC) often have metastatic disease at the time of diagnosis, the development of efficient systemic treatment options for MTC is important." | ( Forssell-Aronsson, E; Montelius, M; Nilsson, O; Sandblom, V; Shubbar, E; Spetz, J; Ståhl, I; Swanpalmer, J, 2020) |
| "We first treated two human papillary thyroid cancer cell lines (KTC-1 and TPC-1) with single or combined administration, and examined the effects on proliferation, the cell cycle, apoptosis, and invasion/migration of papillary thyroid cancer cells." | ( Bian, P; Hu, W; Li, L; Liu, C, 2020) |
| "All patients with unresectable thyroid cancer first treated with lenvatinib between May and November 2015 were registered." | ( Ito, K; Kiyota, N; Sakata, Y; Tahara, M; Takahashi, S; Tori, M; Yoshida, A; Yoshida, K, 2020) |
| "Patients with advanced differentiated thyroid cancer develop resistance to lenvatinib treatment from metabolic dysregulation." | ( Blagg, BSJ; Cohen, MS; Ge, D; Gorney, R; Subramanian, C; Wang, T; Zhang, N; Zuo, A, 2021) |
| "Anaplastic thyroid cancer (ATC) is a rare malignancy and has a poor prognosis due to its aggressive behavior and resistance to treatments." | ( Bao, J; Cheng, X; Wang, X; Wu, J; Wu, L; Xu, S; Yu, H; Zhang, L; Zheng, J, 2020) |
| "The patient also had breast and thyroid cancers history and had undergone various therapeutic modalities such as chemotherapy, thyroid surgery, and breast surgery." | ( Astowo, P; Irawan, B; Magdalena, L; Maha, IHRT; Muthalib, A; Rinaldi, I; Susanto, N; Wicaksono, S, 2020) |
| "Although TKIs are promising agents for thyroid cancer treatment, they are unlikely to lead to a cure." | ( Chino, T; Ito, KI; Ito, T; Kanai, T; Maeno, K; Oba, T; Ono, M; Shimizu, T; Soma, A, 2020) |
| "The pathological findings of primary thyroid cancer, diagnostic method for unusual metastases, and treatment responses of unusual metastases were examined." | ( Hong, AR; Jeon, MJ; Kang, HC; Kim, BH; Kim, HK; Kim, M; Kim, WB; Shin, DY; Shong, YK; Yoon, JH, 2020) |
| "A 40-year-old woman with follicular thyroid cancer underwent a systemic PET/CT evaluation before operation and then received total thyroidectomy and radioactive 131I ablation therapy." | ( Gao, Q; Guo, X; He, H; Jin, Y, 2021) |
| "Anaplastic thyroid cancer (ATC) is a rare, but nearly uniformly fatal disease that is typically resistant to chemotherapy and radiation." | ( Ailles, L; Barrett, JW; Boutros, PC; Datti, A; Fung, K; Ghasemi, F; Han, MW; Khan, IM; MacNeil, D; Meens, J; Mundi, N; Mymryk, JS; Nichols, AC; Patel, K; Pinto, N; Prokopec, SD; Ruicci, KM; Yoo, J, 2020) |
| "Patients with differentiated thyroid cancer who are referred to RAI therapy at the National Cancer Institute, Sri Lanka, will be randomized into two arms consisting of 200 patients each." | ( Jayarajah, U; Seneviratne, SA; Wijekoon, M, 2020) |
| "Moreover, two human thyroid cancer cell lines, differentiated thyroid papillary BCPAP cells and follicular follicular thyroid cancer-131 cells, were treated with different concentrations of the PPARγ agonist rosiglitazone alone or in combination with the RXR agonist bexarotene." | ( Chen, JY; Chi, CW; Hsu, YC; Lee, CH; Lee, HC; Wang, JJ, 2020) |
| "We report two cases of anaplastic thyroid cancer (ATC) which had a very good response to a treatment with lenvatinib at 14 mg." | ( Barbaro, D; Lapi, P; Torregrossa, L; Viacava, P, 2020) |
| "In the earlier report, thyroid cancer incidence was higher in patients primarily treated with antithyroid drugs (3." | ( La Vecchia, C; Negri, E; Turati, F, 2022) |
| "Non-medullary thyroid cancer (NMTC) treatment is based on the ability of thyroid follicular cells to accumulate radioactive iodide (RAI)." | ( Corver, WE; Crezee, T; Kimura, S; Kuiper, JG; Morreau, J; Nagarajah, J; Netea-Maier, RT; Plantinga, TS; Pritchard, C; Smit, JWA; Tesselaar, MH; van Engen-van Grunsven, I, 2021) |
| "Though the majority of differentiated thyroid cancer (DTC) patients have a good prognosis after careful and standardized therapy, approximately 13% to 15% of DTC cases show surprisingly aggressive behavior and invasion of the surrounding structures, and a few progress to unresectable diseases." | ( Deng, X; Ding, Z; Fan, Y; Guo, B; Kang, J; Wu, B; Zhang, Y, 2021) |
| "Radioiodine refractory differentiated thyroid cancer (RAIR-DTC) has been a global challenge due to its poor prognosis and limited treatment options." | ( Guan, WM; Liang, J; Lin, YS; Liu, YQ; Wang, C; Zhang, X, 2021) |
| "Clinically, thyroid cancers are managed with resections and adjuvant therapy with radioiodine." | ( Lai, CL; Yan, Z; Yang, M, 2021) |
| "Lenvatinib is effective in the treatment of RR thyroid carcinoma." | ( Lai, CL; Yan, Z; Yang, M, 2021) |
| "Anaplastic thyroid cancer (ATC) has dismal prognosis and there is no effective treatment." | ( Ahn, MJ; Chung, JH; Jung, HA; Kim, SW; Kim, TH; Lee, SH; Park, J; Park, K; Park, WY; Shim, JH, 2021) |
| "Since treatment for primary thyroid cancer and non thyroid malignancy is totally different, precise diagnosis is clinically important." | ( Erul, E; Güllü, İ; Güven, DC; Şahin, TK, 2021) |
| "Accordingly, most BRAFV600E papillary thyroid cancers (PTC) are refractory to radioiodide (RAI) therapy." | ( Cracchiolo, JR; de Stanchina, E; Fagin, JA; Ho, AL; Im, SY; Knauf, JA; Krishnamoorthy, GP; Leach, SD; Leandro-Garcia, LJ; Lester, R; Lowe, SW; Luckett, KA; Nagarajah, J; Saqcena, M; Sherman, EJ; Zhao, Z, 2021) |
| "Our data demonstrate that KA kills thyroid cancer cell lines by inhibiting their glycolysis ability, the MAPK/ERK pathway and the Bcl-2 level and suggest that KA has potential clinical value in thyroid cancer therapy." | ( Gao, Z; Jing, C; Li, Y; Wang, R, 2022) |
| "Metastatic medullary thyroid cancer (MTC) is a rare malignancy with minimal treatment options." | ( Al Riyami, K; Baldeweg, SE; Bomanji, J; Caplin, ME; Crawford, A; Grossman, AB; Grozinsky-Glasberg, S; Harry, A; Hayes, AR; Khoo, B; Morganstein, D; Nicolas, GP; Oleinikov, K; Tang, C; Wild, D, 2021) |
| "In differentiated thyroid cancer (DTC), the standard treatment includes total thyroidectomy and lifetime levothyroxine (LT4) replacement." | ( Altuntaş, SÇ; Hocaoğlu, Ç, 2021) |
| "The clinical management of anaplastic thyroid cancer (ATC) remains challenging, and novel treatment methods are needed." | ( Chen, S; Jing, H; Li, Y; Sun, Q; Yu, X, 2022) |
| "Experimental animal studies point at thyroid cancer in rats and liver cancer in mice, while multiple organs were affected following the long-term oral administration of Mancozeb." | ( Cocco, P, 2022) |
| "Anaplastic thyroid cancer (ATC) is among the most aggressive of human cancers, and currently there are few effective treatments for most patients." | ( Copland, JA; Mackay, RP; Mahdavian, E; Weinberger, PM; Xu, Q, 2022) |
| "Vitamin D treatment of thyroid cancer cell lines reduces cell migration independently from the inhibition of the secretion of pro-tumorigenic chemokines." | ( Chiovato, L; Coperchini, F; Croce, L; Greco, A; Grillini, B; Magri, F; Petrosino, E; Rotondi, M, 2022) |
| "Anaplastic thyroid cancer (ATC) is an aggressive malignancy without effective treatments." | ( Aggarwal, A; Im, SY; Landa, I; Nehs, MA; Viswanathan, K; Zhao, B, 2022) |
| "Because few drugs are available for thyroid cancer, efforts for continuing treatment with one agent, such as "dose escalation (DE)", are made." | ( Akaishi, J; Hames, KY; Ito, K; Kitagawa, W; Masaki, C; Matsuzu, K; Nagahama, M; Ohkuwa, K; Sugino, K; Suzuki, A; Tomoda, C, 2022) |
| "Anaplastic thyroid cancer (ATC) is a rare and highly aggressive cancer for which effective systemic therapy has long been sought." | ( Hara, H; Hibi, Y; Higashiyama, T; Ioji, T; Ito, KI; Kaneda, H; Katoh, H; Kiyota, N; Kojima, S; Nakashima, N; Nemoto, T; Onoda, N; Ota, I; Suganuma, N; Sugino, K; Sugitani, I; Tahara, M; Takahashi, S; Tori, M; Yane, K, 2022) |
| "Anaplastic thyroid cancer (ATC) is one of the most lethal solid tumors, yet there are no effective, long-lasting treatments for ATC patients." | ( Amiel, E; Carr, FE; Davidson, CD; Tomczak, JA, 2022) |
| "For differentiated thyroid cancer (DTC) patients with thyroglobulin (Tg) elevation and negative iodine scintigraphy (commonly termed "TENIS" syndrome) after thyroidectomy, radioactive iodine (RAI) therapy, and thyroid-stimulating hormone (TSH) suppression therapy, empirical RAI therapy may be considered." | ( Chen, P; Feng, H; Luo, J; Ouyang, W; Pan, L; Wang, J; Wu, J; Xie, J; Xiong, X; Yuan, L, 2023) |
| "Anaplastic thyroid cancer (ATC) is one of the fatal cancers and has not effective treatments." | ( Cai, Y; Ge, J; Ge, M; Guo, Y; Hu, Y; Li, Q; Liu, Y; Ma, W; Song, F; Wang, J; Wen, Q; Yin, C; Zeng, Q; Zheng, G; Zhu, L, 2023) |
| "Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment." | ( Li, H; Li, S; Li, TT; Liu, J; Lu, MD; Nie, JH; Wu, ML; Ye, HS, 2022) |
| "Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment." | ( Li, H; Li, S; Li, TT; Liu, J; Lu, MD; Nie, JH; Wu, ML; Ye, HS, 2022) |
| "Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment." | ( Li, H; Li, S; Li, TT; Liu, J; Lu, MD; Nie, JH; Wu, ML; Ye, HS, 2022) |
| "Advanced thyroid cancer patients treated with tyrosine kinase inhibitors (TKI) can develop several adverse events (AEs), including adrenal insufficiency (AI)." | ( Agate, L; Elisei, R; Giani, C; Matrone, A; Minaldi, E; Molinaro, E; Pontillo-Contillo, B; Valerio, L, 2023) |
| "Anaplastic thyroid cancer (ATC) is one of the most aggressive solid cancers in humans, with limited treatment options." | ( Cheng, SY; Doolittle, WKL; Zhao, L; Zhu, X, 2023) |
| "Anaplastic thyroid cancer (ATC) is one of the most aggressive and lethal tumor types, characterized by loss of differentiation, epithelial-to-mesenchymal transition, extremely high proliferation rate, and generalized resistance to therapy." | ( Di Cristofano, A; Huynh, LD; Shabro, A; Sugarman, AJ, 2023) |
| "The management of papillary thyroid cancer and the role of treatment modalities in prognosis depend on the biological behavior of the tumor." | ( Akhanlı, P; Bayır, Ö; Çakal, E; Düğer, H; Kertmen, H; Kızılgül, M; Korkmaz, MH; Saylam, G; Sencar, ME; Uçan, B; Yazılıtaş, D; Yılmazer, D, 2023) |
| "We screened 167 patients with thyroid cancer [papillary thyroid cancer (PTC), n = 102; follicular thyroid cancer (FTC), n = 26; anaplastic thyroid cancer (ATC), n = 39] who underwent lenvatinib therapy." | ( Hasegawa, C; Hayashi, H; Iwasaki, H; Miyagi, Y; Okubo, Y; Ono, K; Sato, S; Toda, S; Washimi, K; Yokose, T; Yoshioka, E, 2023) |
| "Most patients with differentiated thyroid cancer have a good prognosis after radioactive iodine-131 treatment, but there are still a small number of patients who are not sensitive to radioiodine treatment and may subsequently show disease progression." | ( Bai, Y; Deng, Z; Li, Z; Liu, C; Liu, P; Liu, Y; Lv, J; Lv, L; Zhang, L; Zhang, M; Zou, H, 2023) |
| "Differentiated thyroid cancer (DTC) treatment is based on the ability of thyroid follicular cells to accumulate radioactive iodide (RAI)." | ( Bao, J; Cheng, X; Gao, W; Qiu, L; Wang, Y; Wu, J; Xu, S; Yu, H; Zhang, L, 2023) |